Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company developing treatments for neurodegenerative disorders, has announced the publication of a United States patent application covering a proprietary manufacturing process for benzgalantamine, the active pharmaceutical ingredient in its approved Alzheimer’s disease medicine ZUNVEYL. Announced on October 13, 2026, the development concerns U.S. Patent Application No. 19/090,242, published by the United States Patent and Trademark Office on October 1 as US 2026/0297103 A1, under the title Process for Preparing Benzgalantamine and Salts Thereof.
The application describes manufacturing methods intended to improve synthesis efficiency, control impurities, maintain product quality and support the scalable production of high-purity benzgalantamine. It also addresses the preparation of benzgalantamine salts and related pharmaceutical compositions, extending Alpha Cognition’s intellectual property strategy beyond existing patents associated with drug formulations, solid forms and dosing regimens. The company believes these manufacturing innovations could support the long-term commercial development of ZUNVEYL, which received United States Food and Drug Administration approval in July 2024 for mild-to-moderate dementia of the Alzheimer’s type in adults.
The announcement comes as Alpha Cognition expands its commercial business following ZUNVEYL’s March 2025 launch. The company reported approximately $6 million in second-quarter 2026 net product revenue, representing 71% growth from the preceding quarter, alongside increased prescribing activity and penetration of long-term care facilities. A reliable manufacturing process could become increasingly relevant if prescription demand continues growing, although the company has not disclosed quantified cost savings, production-yield improvements or manufacturing capacity increases attributable to the patent application.
The regulatory and legal status requires an important distinction. The patent application has been published but has not been granted, meaning the disclosed claims do not currently constitute newly issued patent rights. Alpha Cognition’s earlier regulatory filings identified an estimated March 2045 expiration date for the proposed manufacturing patent, subject to successful prosecution and applicable adjustments, but the eventual scope and enforceability of any protection remain uncertain.
What does Alpha Cognition’s new benzgalantamine manufacturing patent application actually cover?
The newly published application focuses on the process used to prepare benzgalantamine and its salts rather than on establishing a new clinical use for the medicine. According to Alpha Cognition, the disclosed technology incorporates manufacturing innovations intended to improve production efficiency while controlling impurities and other critical product characteristics. These factors are relevant to the consistent preparation of active pharmaceutical ingredients used in regulated medicines.
Benzgalantamine manufacturing requires control over chemical identity, purity and other quality attributes that can affect downstream pharmaceutical production. Variability in the synthesis process can influence the impurity profile, manufacturing yield and consistency of material supplied for formulation. A process that reliably produces material meeting predefined specifications may therefore offer operational advantages, particularly as production volumes increase.
The patent application also addresses preparation of benzgalantamine salts and related pharmaceutical compositions. These elements could provide additional protection around particular manufacturing approaches or materials if the relevant claims are ultimately granted. However, the precise commercial significance will depend on the final claims and whether the protected processes offer advantages over other technically feasible manufacturing methods.
Alpha Cognition has not disclosed quantitative comparisons demonstrating improved yield, lower production costs or reduced manufacturing cycle times. Nor has it established that the proposed processes are already being used throughout its commercial supply chain. The technology’s potential contribution to manufacturing efficiency remains a company objective rather than an independently measured operating improvement.
Why could a manufacturing process patent matter for ZUNVEYL’s long-term commercial position?
Pharmaceutical intellectual property portfolios frequently extend beyond patents covering the active compound itself. Manufacturers may seek protection for specific solid forms, formulations, drug delivery systems, dosing regimens and manufacturing processes. These different categories can protect distinct aspects of a medicine’s development and production, although their commercial reach depends on the scope of the claims.
For ZUNVEYL, manufacturing protection could become relevant if the disclosed process offers a technically advantageous way to produce high-purity benzgalantamine at commercial scale. Patent rights covering such a process could potentially restrict competitors from using the protected method without authorization. However, they would not necessarily prevent another manufacturer from developing benzgalantamine using a different process that does not infringe the relevant claims.
This distinction makes manufacturing patents different from broad protection covering a pharmaceutical compound. A process patent may provide a valuable barrier where alternative production routes are difficult or economically unattractive, but its effectiveness depends on technological differentiation and the ability to establish infringement. The existence of an application does not establish those conditions.
Alpha Cognition Chief Executive Officer Michael McFadden described the publication as another step in building broader intellectual property protection around benzgalantamine and ZUNVEYL. Management believes improved process control and manufacturing scalability could support the product’s longer-term commercial potential. The assessment is consistent with the company’s established patent strategy, although the resulting commercial benefits remain contingent on patent prosecution and manufacturing execution.
Does the October 2026 patent publication extend ZUNVEYL’s protection through 2045?
The company’s patent portfolio already includes several granted United States patents with different expiration dates and scopes of protection. Its 2025 annual report identified the benzgalantamine manufacturing application as part of the Blood Brain Barrier IX intellectual property family, with an estimated expiration date of March 25, 2045. That estimate concerns the potential term of a patent that has not yet been granted.
The company has secured other rights relevant to the ZUNVEYL franchise. United States Patent No. 12,208,167 covers coated tablets designed for pH-dependent benzgalantamine release, with an estimated expiration in February 2044. Another patent, No. 12,551,491, issued in February 2026, covers specific benzgalantamine dosing regimens and has an estimated protection period extending into July 2045.
Additional patents and pending applications address specific solid forms of benzgalantamine gluconate, delivery approaches and pharmacokinetic characteristics. Together, these protections are intended to create multiple layers of intellectual property around the commercial product and related development programmes. Nevertheless, the scope of each patent differs, and overlapping expiration dates do not establish that every potential competing product would necessarily be excluded until 2045.
The October publication also does not automatically extend FDA-administered regulatory exclusivity. Patent protection and regulatory exclusivity operate through different legal mechanisms, and a newly published manufacturing application does not itself create additional FDA exclusivity. The ability to enforce any eventual patent will depend on the claims that issue, their validity and the relevant competing activity.
For Alpha Cognition, the immediate achievement is public disclosure of another pending application within its intellectual property portfolio. The more consequential future milestone would be issuance of a patent with commercially meaningful claims that withstand potential challenges.
How is ZUNVEYL differentiated from conventional galantamine treatments for Alzheimer’s disease?
ZUNVEYL is a delayed-release oral formulation containing benzgalantamine, a prodrug that is converted into galantamine after administration. Galantamine inhibits acetylcholinesterase, an enzyme involved in breaking down acetylcholine, a neurotransmitter associated with memory and other cognitive functions. Increasing acetylcholine availability can provide symptomatic benefits in patients with Alzheimer’s dementia, although this mechanism does not establish prevention or reversal of the underlying neurodegenerative disease.
The FDA approved ZUNVEYL on July 26, 2024, through the 505(b)(2) regulatory pathway, relying in part on established evidence concerning galantamine. The approved indication covers treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. The product is available as delayed-release tablets containing 5 mg, 10 mg and 15 mg of benzgalantamine, with twice-daily administration and dose escalation according to the prescribing information.
Alpha Cognition positions the formulation around its enteric-coated, delayed-release technology, which is intended to limit drug release in the stomach. The company believes this pharmacological design may help address gastrointestinal tolerability concerns associated with conventional acetylcholinesterase inhibitors. However, the FDA approval does not establish that ZUNVEYL is clinically superior to donepezil, rivastigmine or conventional galantamine in a randomized head-to-head efficacy trial.
The approved prescribing information retains important safety considerations associated with cholinesterase inhibition. These include serious skin reactions, bradycardia and other cardiac conduction abnormalities, as well as gastrointestinal and respiratory precautions. The most common adverse reactions associated with galantamine tablets include nausea, vomiting, diarrhoea, dizziness, headache and decreased appetite.
The manufacturing patent announcement does not change these approved indications, dosing requirements or safety warnings. It concerns the production of benzgalantamine rather than a newly demonstrated therapeutic benefit or a change to the product’s clinical characteristics.
Why does manufacturing reliability matter as ZUNVEYL sales and prescriptions increase?
Alpha Cognition’s commercial performance provides a practical explanation for its continuing investment in manufacturing-related intellectual property. During the second quarter of 2026, ZUNVEYL generated approximately $6 million in net product revenue, compared with $3.5 million during the first quarter. The 71% sequential increase reflected higher prescription demand and expanding use within the company’s targeted long-term care market.
The company reported that 8,294 bottles were dispensed during the quarter, an increase of approximately 37% from 6,054 bottles in the preceding period. Monthly demand reached 2,997 bottles in June, while the number of prescribing healthcare professionals increased to 1,347. Repeat prescribers rose to 1,024, representing approximately 76% of the quarter’s prescriber population.
Alpha Cognition also reported prescriptions originating from 1,095 long-term care facilities during the second quarter. The company has concentrated its commercial strategy on nursing homes and other institutional settings where residents with Alzheimer’s dementia often receive multiple medicines and require continuing treatment supervision. That market focus creates a need for reliable product supply and consistent pharmaceutical quality.
A growing prescription base can increase the importance of active ingredient availability, production scheduling and inventory management. Manufacturing interruptions or inconsistent supply could affect pharmacy fulfilment and relationships with long-term care customers. Processes that improve reliability may therefore have commercial value even if they do not change the medicine’s clinical performance.
However, Alpha Cognition has not established a direct connection between the newly published patent application and its second-quarter revenue growth. The manufacturing disclosure did not include a new production agreement, a validated capacity expansion or a quantified reduction in cost of goods. The commercial relevance remains prospective and should be assessed separately from the company’s reported prescription growth.
What do the latest CONVERGE findings suggest about ZUNVEYL adoption in long-term care?
Alpha Cognition’s October 1, 2026 disclosure of initial CONVERGE findings adds clinical practice context to the company’s expanding commercial operations. The ongoing retrospective research programme examines medication-administration records from long-term care residents receiving ZUNVEYL or commonly prescribed generic acetylcholinesterase inhibitors. Its initial analysis focused on treatment titration and changes in concomitant medication use over 180 days.
Among residents who had not previously received an acetylcholinesterase inhibitor and began treatment at the starting dose, 79.1% of ZUNVEYL recipients reached a therapeutic dose compared with 37.3% receiving generic acetylcholinesterase inhibitors. In the broader treatment-naive population, the corresponding percentages were 79.2% and 53.7%. Among residents switching from an earlier acetylcholinesterase inhibitor, 80.7% of ZUNVEYL recipients reached a therapeutic dose compared with 54.0% of generic-treatment recipients.
These findings suggest differences in real-world dosing patterns, potentially relevant to treatment management in institutional settings. However, the analysis was observational and retrospective rather than a randomized comparison. Prescriber selection, baseline patient characteristics, previous tolerability and differences in care practices may influence the observed results.
The analysis also examined changes in concomitant medication classes, reporting different patterns between the ZUNVEYL and generic-treatment cohorts. These observations may help generate hypotheses concerning treatment tolerability and medication management, but they do not establish that ZUNVEYL caused reductions in other drug use or improved cognitive outcomes. The full evidence will require examination of potential confounding factors and the clinical significance of the reported changes.
For Alpha Cognition, the combination of prescription growth and continuing real-world evidence generation provides a broader commercial setting for the manufacturing patent strategy. The company is working to establish ZUNVEYL within a competitive category while building the evidence and infrastructure needed for sustained product adoption.
How do Alpha Cognition’s finances support its commercial expansion and patent strategy?
Alpha Cognition reported approximately $41.4 million in cash, cash equivalents and short-term investments as of June 30, 2026. The company also reported a second-quarter net loss of approximately $8.8 million, compared with $13.2 million during the corresponding period of 2025. These figures reflect a business that is generating growing commercial revenue while continuing to invest in sales infrastructure, clinical programmes and product development.
Second-quarter research and development expenditure reached approximately $2 million, compared with $406,000 a year earlier. Selling, general and administrative expenses were approximately $11.5 million, reflecting continuing commercialization costs. Management reduced its full-year 2026 operating expense guidance for research and development and selling, general and administrative activities to $50 million to $54 million.
The company continues to target operating profitability in 2027, although that objective remains dependent on revenue growth, operating expenditure and market access. In August, management reported that Medicare Part D contracts with two major pharmacy benefit managers represented approximately 45 million covered lives. The agreements provide potential access opportunities, but contracted coverage should not be equated with unrestricted reimbursement for every eligible patient.
The patent application adds another strategic consideration to this financial outlook. Stronger manufacturing processes could potentially support gross margins and supply reliability as commercial volume expands. However, the company’s reported second-quarter gross margin of approximately 94% cannot be attributed to the newly disclosed process, and no evidence establishes that the application will improve profitability.
Alpha Cognition shares closed at $8.84 on October 12, declining approximately 2.2% during the session before the patent announcement. The stock had traded between approximately $4.50 and $10.14 over the preceding 52 weeks, indicating substantial variation in market valuation. The October 12 price movement cannot be attributed to the October 13 publication announcement, and the disclosure itself does not establish an immediate change in revenue or earnings.
Investor assessments are likely to remain more closely connected to prescription growth, reimbursement progress, operating losses and the company’s ability to achieve its profitability target. Intellectual property developments may influence long-term expectations, but their economic value is more difficult to quantify before the corresponding rights are granted and commercial advantages are demonstrated.
Could the manufacturing process support future benzgalantamine formulations and indications?
Alpha Cognition’s benzgalantamine development strategy extends beyond the currently approved delayed-release oral tablet. The company has investigated alternative delivery approaches intended to address the needs of patients who may have difficulty swallowing conventional oral medicines. It has also explored additional neurological indications for ALPHA-1062, the development designation associated with benzgalantamine.
The company’s sublingual formulation programme is particularly relevant because swallowing difficulties can complicate treatment in patients with cognitive impairment and advancing neurological disease. Alpha Cognition has indicated that it intends to advance the programme toward clinical evaluation in 2027, with the objective of developing an alternative administration option. The formulation remains investigational and is not authorized as a substitute for the existing oral tablet.
Additional programmes involving benzgalantamine in combination with memantine and potential neurological indications remain subject to their respective development requirements. Manufacturing technology capable of producing pharmaceutical-grade active ingredient consistently could support research across different formulations, although each candidate may require distinct manufacturing, stability and regulatory evidence.
The patent application’s references to benzgalantamine salts and pharmaceutical compositions may therefore have relevance beyond the current ZUNVEYL product. However, the eventual claims and their applicability to future formulations cannot be assumed from the publication announcement alone. Nor does manufacturing protection establish that any additional formulation or indication will achieve regulatory approval.
What must Alpha Cognition demonstrate before the manufacturing patent delivers commercial value?
The next important intellectual property milestone will be the progress of U.S. Patent Application No. 19/090,242 through examination by the United States Patent and Trademark Office. The patent office will assess whether the claimed inventions satisfy the applicable requirements, including novelty, nonobviousness and sufficient disclosure. The final claims may differ substantially from those originally submitted, and issuance is not guaranteed.
Commercial validation presents a separate challenge. Alpha Cognition will need to demonstrate that the manufacturing methods provide useful operating advantages, such as reliable product quality, improved process efficiency or more consistent supply. Those benefits would be particularly relevant as the company’s prescription volumes expand, but they remain distinct from the legal question of whether the underlying process is patentable.
The competitive significance of an eventual patent will depend on whether the protected method is difficult to reproduce using alternative approaches. Narrow process claims may still be valuable if they protect an economically efficient manufacturing route, but they do not necessarily prevent other companies from producing the same active ingredient through different methods. The company’s existing patents covering formulations and dosing regimens will therefore remain important components of its broader protection strategy.
For Alpha Cognition, the October 2026 publication is best understood as an incremental intellectual property development accompanying the commercialization of an already approved Alzheimer’s medicine. It strengthens the visibility of the company’s manufacturing-related inventions without creating new clinical evidence, regulatory exclusivity or confirmed commercial savings.
The most meaningful measure of progress will be whether Alpha Cognition secures enforceable patent rights and demonstrates manufacturing improvements that support reliable supply as ZUNVEYL demand grows. With quarterly revenue reaching $6 million and management targeting operating profitability in 2027, the company has increasingly practical reasons to invest in production efficiency and intellectual property protection. The new application could contribute to that strategy, but its long-term significance will depend on successful patent prosecution, commercially useful manufacturing performance and continued execution of the ZUNVEYL business.
